Medical College of Wisconsin: Myelodysplastic Syndromes trials

The registry lists 10 Myelodysplastic Syndromes studies with Medical College of Wisconsin as lead sponsor. 2 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 4Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic TransplantNot yet recruitingNCT07572929Phase 2
• Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic SyndromeRecruitingNCT06502145Phase 1
• TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)CompletedNCT03959241Phase 3Results posted
• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)TerminatedNCT03150004Phase 2Results posted
• Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)CompletedNCT02016781Phase 2Results posted
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)TerminatedNCT01339910Phase 3Results posted
• Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)CompletedNCT00412360Phase 3Results posted
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)CompletedNCT00406393Phase 3Results posted
• Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic TransplantTerminatedNCT03588936Phase 1
• Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow TransplantationStatus unknownNCT00036712Phase 2